SI2953941T1 - Modulatorji metil-modificirajočih encimov, sestavki in uporabe le-teh - Google Patents

Modulatorji metil-modificirajočih encimov, sestavki in uporabe le-teh

Info

Publication number
SI2953941T1
SI2953941T1 SI201430274T SI201430274T SI2953941T1 SI 2953941 T1 SI2953941 T1 SI 2953941T1 SI 201430274 T SI201430274 T SI 201430274T SI 201430274 T SI201430274 T SI 201430274T SI 2953941 T1 SI2953941 T1 SI 2953941T1
Authority
SI
Slovenia
Prior art keywords
modulators
compositions
modifying enzymes
methyl modifying
methyl
Prior art date
Application number
SI201430274T
Other languages
English (en)
Inventor
Brian K. Albrecht
James Edmund Audia
Andrew S. Cook
Les A. Dakin
Martin Duplessis
Victor S. Gehling
Jean-Christophe Harmange
Christopher G. Nasveschuk
Rishi G. Vaswani
Original Assignee
Constellation Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50239937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2953941(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2013/025639 external-priority patent/WO2013120104A2/en
Application filed by Constellation Pharmaceuticals, Inc. filed Critical Constellation Pharmaceuticals, Inc.
Publication of SI2953941T1 publication Critical patent/SI2953941T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
SI201430274T 2013-02-11 2014-02-11 Modulatorji metil-modificirajočih encimov, sestavki in uporabe le-teh SI2953941T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2013/025639 WO2013120104A2 (en) 2012-02-10 2013-02-11 Modulators of methyl modifying enzymes, compositions and uses thereof
EP14708987.4A EP2953941B1 (en) 2013-02-11 2014-02-11 Modulators of methyl modifying enzymes, compositions and uses thereof
PCT/US2014/015706 WO2014124418A1 (en) 2013-02-11 2014-02-11 Modulators of methyl modifying enzymes, compositions and uses thereof

Publications (1)

Publication Number Publication Date
SI2953941T1 true SI2953941T1 (sl) 2017-08-31

Family

ID=50239937

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201430274T SI2953941T1 (sl) 2013-02-11 2014-02-11 Modulatorji metil-modificirajočih encimov, sestavki in uporabe le-teh

Country Status (17)

Country Link
EP (1) EP2953941B1 (sl)
KR (1) KR102219441B1 (sl)
CN (1) CN105102446B (sl)
CL (1) CL2015002239A1 (sl)
CR (1) CR20150457A (sl)
HK (1) HK1218648A1 (sl)
IL (1) IL239985B (sl)
MA (1) MA38341B1 (sl)
ME (1) ME02730B (sl)
PE (1) PE20160044A1 (sl)
PH (1) PH12015501720A1 (sl)
PL (1) PL2953941T3 (sl)
RS (1) RS56207B1 (sl)
SG (1) SG11201506077XA (sl)
SI (1) SI2953941T1 (sl)
TW (1) TWI629273B (sl)
WO (1) WO2014124418A1 (sl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
ES2722048T3 (es) 2014-12-23 2019-08-07 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos
WO2016130396A1 (en) * 2015-02-13 2016-08-18 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US20180214519A1 (en) 2015-07-24 2018-08-02 Constellation Pharmaceuticals, Inc. Combination therapies for modulation of histone methyl modifying enzymes
US20180221362A1 (en) 2015-08-03 2018-08-09 Constellation Pharmaceuticals, Inc. Ezh2 inhibitors and modulation of regulatory t-cell function
US10493076B2 (en) 2015-08-24 2019-12-03 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
WO2017040190A1 (en) * 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
EA201890878A1 (ru) 2015-10-06 2018-08-31 Эпизайм, Инк. Способ лечения медуллобластомы с помощью ингибитора ezh2
EP3371601A1 (en) 2015-11-05 2018-09-12 Epizyme Inc Flow cytometry for monitoring histone h3 methylation status
JP2019503391A (ja) 2016-01-29 2019-02-07 エピザイム,インコーポレイティド 癌を処置するための併用療法
CN105669647B (zh) * 2016-02-22 2018-05-04 上海皓元生物医药科技有限公司 一种组蛋白甲基化酶ezh2抑制剂中间体的合成方法
MA45406A (fr) 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer
US11091489B2 (en) 2016-06-20 2021-08-17 Novartis Ag Crystalline forms of a triazolopyrimidine compound
ES2798424T3 (es) 2016-06-20 2020-12-11 Novartis Ag Compuestos de triazolopiridina y usos de estos
US10676479B2 (en) 2016-06-20 2020-06-09 Novartis Ag Imidazolepyridine compounds and uses thereof
US10457640B2 (en) 2016-10-19 2019-10-29 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of EZH2
WO2018102687A2 (en) 2016-12-02 2018-06-07 Epizyme, Inc. Combination therapy for treating cancer
CA3050221C (en) 2017-01-19 2021-09-28 Daiichi Sankyo Company, Limited Pharmaceutical composition used for treatment of htlv-1-associated myelopathy
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
US20230201212A1 (en) 2017-06-13 2023-06-29 Epizyme, Inc. Inhibitors of ezh2 and methods of use thereof
US20210161883A1 (en) 2017-07-10 2021-06-03 Constellation Pharmaceuticals, Inc. Ezh2 inhibitor-induced gene expression
EP3707136B1 (en) 2017-11-09 2022-05-04 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
SG11202003477QA (en) 2017-11-14 2020-05-28 Pfizer Ezh2 inhibitor combination therapies
CN109879790B (zh) * 2017-12-06 2022-09-20 华东师范大学 以吲哚或吲哚类似物为母核结构的酰胺类小分子有机化合物、用途及其制备方法
US20210000815A1 (en) 2017-12-28 2021-01-07 Constellation Pharmaceuticals, Inc. Pharmacokinetic enhancement of ezh2 inhibitors through combination therapies
CN112004816B (zh) 2018-01-31 2024-01-05 米拉蒂医疗股份有限公司 Prc2抑制剂
CN110229157B (zh) * 2018-03-06 2022-06-21 上海海和药物研究开发股份有限公司 嘧啶并五元芳香杂环类化合物、其制备方法及用途
CN110229151B (zh) * 2018-03-06 2021-09-10 上海海和药物研究开发股份有限公司 吲嗪类化合物、其制备方法及用途
WO2019178191A1 (en) 2018-03-14 2019-09-19 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
JP2022500472A (ja) 2018-09-19 2022-01-04 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. O−糖タンパク質−2−アセトアミド−2−デオキシ−3−d−グルコピラノシダーゼ阻害剤
AR117252A1 (es) 2018-12-05 2021-07-21 Biogen Ma Inc Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de morfolinilo, piperazinilo, oxazepanilo y diazepanilo
WO2020139339A1 (en) 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
US20220106305A1 (en) 2019-02-04 2022-04-07 Biogen Ma Inc. Bicyclic ether o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
US20220259197A1 (en) 2019-03-08 2022-08-18 Biogen Ma Inc. Azetidinyl o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
CA3148447A1 (en) * 2019-07-24 2021-01-28 Constellation Pharmaceuticals, Inc. Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxa mide
CN118236503A (zh) 2019-07-24 2024-06-25 星座制药公司 用于治疗癌症的ezh2抑制联合疗法
US20230060003A1 (en) 2019-10-29 2023-02-23 Biogen Ma Inc. Spirocyclic o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
BR112023002013A2 (pt) 2020-08-03 2023-05-02 Biogen Ma Inc Formas cristalinas de um inibidor de o-glicoproteína-2-acetamido-2-desóxi-3-d-glucopiranosidase
CN112679505B (zh) * 2020-12-25 2022-04-22 杭州澳赛诺生物科技有限公司 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法
WO2022150962A1 (en) 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Protease inhibitors, preparation, and uses thereof
WO2023111810A1 (en) 2021-12-14 2023-06-22 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023209591A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2566327T1 (sl) * 2010-05-07 2017-07-31 Glaxosmithkline Llc Indoli
JP2014511389A (ja) * 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換6,5−縮合二環式ヘテロアリール化合物
JO3438B1 (ar) * 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9085583B2 (en) * 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Also Published As

Publication number Publication date
CN105102446B (zh) 2018-01-23
IL239985B (en) 2018-11-29
RS56207B1 (sr) 2017-11-30
KR20150119201A (ko) 2015-10-23
WO2014124418A1 (en) 2014-08-14
TW201443038A (zh) 2014-11-16
ME02730B (me) 2017-10-20
MA38341A1 (fr) 2018-01-31
CL2015002239A1 (es) 2016-02-05
SG11201506077XA (en) 2015-08-28
IL239985A0 (en) 2015-09-24
TWI629273B (zh) 2018-07-11
PL2953941T3 (pl) 2017-11-30
PH12015501720B1 (en) 2015-11-09
PH12015501720A1 (en) 2015-11-09
KR102219441B1 (ko) 2021-02-23
CN105102446A (zh) 2015-11-25
PE20160044A1 (es) 2016-02-11
MA38341B1 (fr) 2018-11-30
EP2953941A1 (en) 2015-12-16
HK1218648A1 (zh) 2017-03-03
EP2953941B1 (en) 2017-04-05
CR20150457A (es) 2015-10-20

Similar Documents

Publication Publication Date Title
HK1218648A1 (zh) 甲基修飾酶的調節劑、其組合物及用途
LT2953941T (lt) Metilą modifikuojančių fermentų moduliatoriai, kompozicijos ir jų naudojimas
IL244081A0 (en) Preparations and methods for modulating RNA
EP2780014A4 (en) METHYLATION MODIFICATION ENZYME MODULATORS, COMPOSITIONS AND USES THEREOF
EP2780013A4 (en) MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
HUE048666T2 (hu) Mezõgazdasági endofita-növény kompozíciók és alkalmazási eljárások
EP2992097A4 (en) Compositions and methods
EP2951283A4 (en) Compositions and methods
IL265876A (en) Preparations that include 15-ohepa and methods of using them
EP3071588A4 (en) Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto
EP3075097A4 (en) Construction and uses of variable-input-length tweakable ciphers
EP3038634A4 (en) Novel sez6 modulators and methods of use
EP2983681A4 (en) Therapeutic compositions and uses thereof
EP3039131A4 (en) Enzyme composition and uses thereof
EP2992334A4 (en) Novel phosphatidylalkanols and compositions thereof
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
EP3087056A4 (en) Glucocerebrosidase modulators and uses thereof
SG11201505891VA (en) Catalyst compositions and methods of making and using same
HK1223632A1 (zh) 靶向的酶化合物及其用途
EP2943575A4 (en) COMPOSITIONS AND METHODS FOR PRODUCING ENZYMES
GB201309178D0 (en) Enzyme and uses thereof
EP3043780A4 (en) Novel delivery compositions and methods of using same
EP2925315A4 (en) BRYOID COMPOSITIONS AND METHODS OF MAKING AND USING THEM
HK1217670A1 (zh) 調配物、其製造方法和用途
EP3052051A4 (en) STABILIZED ENZYME COMPOSITIONS